

Protocol for the development of a rapid advice guidelines for management of children with SARS-CoV-2 infection

Weiguo Li^{1,2,3#}, Qi Zhou^{4,5#}, Yuyi Tang^{1,2,3}, Luo Ren^{1,2,3}, Xuan Yu^{5,6,7,8,9}, Qiu Li^{2,3}, Enmei Liu^{1,2,3}, Yaolong Chen^{5,6,7,8,9}; on behalf of COVID-19 evidence and recommendations working group

¹Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China; ²National Clinical Research Center for Child Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China; ³Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China; ⁴The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China; ⁵Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China; ⁶WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou 730000, China; ⁷Guideline International Network Asia, Lanzhou 730000, China; ⁸Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou 730000, China; ⁹Chinese GRADE Center, Lanzhou 730000, China

#These authors contributed equally to this work.

Correspondence to: Enmei Liu, MD, PhD. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China. Email: emliu186@126.com; Yaolong Chen, MD. Professor, Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. Email: chenyaolong@lzu.edu.cn.

Submitted Feb 09, 2020. Accepted for publication Feb 21, 2020.

doi: 10.21037/apm.2020.02.33

View this article at: <http://dx.doi.org/10.21037/apm.2020.02.33>

Introduction

In December 2019, a new type of Coronavirus that causes pneumonia was first detected in Wuhan, China, and is since then spreading worldwide (1). The virus was named SARS-CoV-2 later on, and the infectious disease was officially named "Corona Virus Disease 2019" (COVID-19) by World Health Organization (WHO) on February 11, 2020. Subsequently, WHO ranked the risk of a global SARS-CoV-2 outbreak to high, saying it poses a very high risk for China and the world (2). To date, over 30,000 cases have been diagnosed and 723 deaths have been confirmed. The virus has now reached several other countries. Two hundred and seventy-four cases had been diagnosed in 24 countries so far including Japan, South Korea, Singapore, UK and the United States (3). The WHO has declared that the new coronavirus outbreak is a public health emergency of international concern on 30 January 2020. Children COVID-19 cases, including adolescents, have also been reported, and their number seems to be on the increase. Current guidelines and recommendations mainly target adults with SARS-CoV-2 infection. Health care providers are in urgent need of a guideline to assist the diagnosis

and management of SARS-COV-2 infected children. Rapid advice guidelines need to be completed in 1 to 3 months, and are designed primarily to respond to public health emergencies, in order to provide timely and rapid guidance to health workers (4). We aim to develop a rapid advice guideline using a multidisciplinary and collaborative approach. The guideline will follow the methods for developing WHO rapid advice guidelines (5), taking into account the special condition of this infectious disease, in order to respond to the health emergency, need for evidence-based guidance.

Methods

The guideline will be developed in accordance with the WHO requirements for rapid advice guideline (4), followed the new guideline definition from the Institute of Medicine (IOM) (6). Other related guidelines on SARS-CoV-2 will be evaluated by the AGREE II instrument (Appraisal of Guidelines for Research and Evaluation) before the guideline development (7). The guideline will meet the criteria of Guideline 2.0 and RIGHT (Reporting Items for

Practice Guidelines in Healthcare) checklist of guideline development version 2.0 (8) and RIGHT statement (9). Gantt chart illustrates the key steps and timeline of the guideline (*Figure S1*).

Guideline developers

The China National Clinical Research Center for Children Health and Disease (Children's Hospital of Chongqing Medical University), Clinical Child Pharmacology Society of Pediatric Academy of Chinese Medical Association, National Clinical Research Center for Infectious Disease (Shenzhen Third People's Hospital), G-I-N Asia, Chinese GRADE Center and WHO Collaborating Centre for Guideline Implementation and Knowledge Translation jointly initiated the development of the guideline.

Guideline registration

The guideline was registered at the International Practice Guidelines Registry Platform (<http://www.guidelines-registry.org/>). The registration No. is IPGRP-2020CN008.

Guideline working groups and declaration of conflicts of interest

The guideline working group consists of a guideline development group and a rapid review group. All members of the guideline working group are required to make a conflicts of interest declaration (10). These declarations will be included as attachments with the final guideline document. The development of the guidelines is supported by a special fund from The China National Clinical Research Center for Children Health and Disease (Children's Hospital of Chongqing Medical University), 2020 Key R & D project of Gansu Province and Prevention and Control of emergency of COVID-19 from Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province (No. GSEBMKT-2020YJ01).

Guideline Development Group

The guideline development group will consist of 37 multidisciplinary experts, including infectious disease physicians, respiratory physicians, public health experts, clinical pharmacists, methodological experts, nurse practitioners, primary care pediatricians, general practitioners, legal experts and global health researchers.

The main responsibilities of the development group are to draft proposal, prioritize clinical questions, participate in Delphi surveys, reach a consensus and approve the guideline. For each recommendation, if it receives more than two thirds of votes then the agreement will be reached.

Rapid Review Group

The rapid review group consists of methodologists and pediatricians. The main responsibilities of the rapid review group are to collect initial clinical questions, conduct rapid reviews, rate the evidence, prepare decision-making tables and take the minutes of guideline meeting.

Guideline scope

The title of the guideline is rapid advice guidelines for management of children with SARS-CoV-2 infection. The guideline is targeted for pediatricians, clinical pharmacists, general practitioners, and nurses in general hospitals, children's hospitals, and primary clinics. The target population and beneficiary of the guideline are children, including adolescents (<18 years). The guideline will contain the following sections: new terms and definitions, symptoms, screening and diagnosis, risk assessment, lab testing and imaging tests, treatments, management, and patient education.

Determination of clinical questions

The clinical questions and outcomes will be collected and sorted out by the members of the rapid review group and sent to the panelist by emails. The development group will add, revise, prioritize and confirm the final set of clinical questions. The guideline is intended to include 10 to 20 clinical questions.

Evidence search

The rapid review group will search and evaluate the evidence. A search strategy will be developed and implemented to identify literature published since 2003 [considering the first novel coronavirus caused the severe acute respiratory syndrome (SARS) outbreak was in 2003] to February 2020. The following databases will be searched: PubMed, EMBASE, Cochrane library, Web of Science, WANFANG, CNKI, and CBM. There will be no restriction on publication type. *Box S1* shows the PubMed

database search as an example.

Evidence screening and data extraction

At least two reviewers will screen the titles, abstracts and full texts in accordance with the inclusion and exclusion criteria of each clinical question independently, then extract the data using a pre-designed data extraction form. In case of disagreements, consensus will be achieved with the help of an experienced third researcher.

Conduct and update systematic review

The rapid review group will first retrieve any existing relevant systematic reviews. If they meet our criteria (published within three years and have high quality evaluated by AMSTAR) (11), the group will adopt them. If they are of high quality but outdated, the group will update them. If they are of low quality, or they do not answer our PICO questions, the group will conduct a new rapid review.

Grade the quality of evidence

The rapid review group will use the GRADE system to rate the evidence (12,13). The evidence will be downgraded according to the following five criteria (risk of bias, inconsistency, indirectness, imprecision and publication bias) or upgraded according to the following three criteria (large magnitude of effect, dose response, confounders likely minimize the effect) (14-19). The final certainty of evidence will be graded as either high, moderate, low or very low (20).

Formulate recommendations and reach consensus

The guideline development group will propose an initial draft set of recommendations and use two rounds of a modified Delphi to reach a consensus by a GRADE Grid table (*Table S1*).

Discussion

Although health staff has been going through the new coronavirus infection diseases like the SARS and MERS for many years, they still lack high-quality guidelines to rely on when in the context of the emergency: SARS-CoV-2 outbreak. The first reason is effective antivirus medication may be limited and some agents probably have worrying

side effects for the children. Some agents used in the clinic are controversial without high-quality evidence to support. Secondly, some unnecessary tests may increase the health care burden, but with no benefit of diagnosis. Moreover, for a fulminating infectious disease, the screening, and management strategy should be standard and efficient. Tremendous health care resources have been put in the control of the virus spread, and it should be used reasonably under a smart policy. There is no doubt that clinical practice guidelines can provide the best recommendations for clinicians based on evidence from systematic reviews (5).

The development of standard guidelines needs to follow a strict methodology and generally requires a period of more than one year. Thus, the time-consuming development has become a major concern for both guideline makers and users (21-22). Therefore, the standard guideline process is not suitable for producing timely guidance and in response to public health emergencies such as the infectious disease SARS and COVID-19. Guideline developers have begun to explore more rapid approaches. WHO proposed the concept of rapid advice guidelines around 2006, which is to be developed over a period of one to three months to respond to the public health emergencies or other needs (23).

Rapid advice guidelines meet the minimum standards as described in the WHO guideline manual, with reasonably modified process and methods that allow to quickly complete the development of the guideline. Therefore, rapid advice guidelines, based on the available up-to-date and high-quality evidence, can help the healthcare providers make quick evidence-based decisions, and its development process is accelerated. WHO has developed ten rapid advice guidelines for the prevention of infectious diseases such as H5N1, HIV, tuberculosis, H1N1, Ebola, and Zika virus (24-29). So far two rapid advice guidelines have been developed in China (30,31). To our best knowledge, this is the first international rapid advice guideline on children with SARS-CoV-2 infection. The guideline will be made available in English, Japanese, Korean, and simplified and traditional Chinese. We believe the guideline will help policy makers, health practitioners and parents take better care of children with SARS-CoV-2 infection.

Acknowledgments

We are extremely thankful to Amir Qaseem, Detty Nurdiati, Edwin Chan, Hongmei Xu, Hyeong Sik Ahn, Janne Estill, Joseph Mathew, Junqiang Lei, Liqun Wu, Lei Liu, Mansuk

Daniel Han, Mengshu Wang, Myeong Soo Lee, Qi Wang, Quan Lu, Ruiqiu Zhao, Rosalind Smyth, Shihui Liu, Shu Yang, Shunyin Zhao, Toshio Fukuoka, Wilson Milton Were, Wenwei Tu, Wong Wing Kin Gary, Xianlan Zheng, Xiaobo Zhang, Xiaodong Zhao, Xiaoping Luo, Xiaoxia Lu, Xixi Feng, Yuan Qian, Zhengxiu Luo, Zhihui He, and Zhou Fu for their comments and revisions on earlier drafts of the paper.

Funding: The project is funded by the following funding agencies: (I) The China National Clinical Research Center for Children Health and Disease (Children's Hospital of Chongqing Medical University); (II) Chongqing technology innovation and application development special project fund; (III) 2020 Key R & D project of Gansu Province, China; (III) Prevention and Control of emergency of COVID-19 from Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province (No. GSEBMKT-2020YJ01).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- World Health Organization. Surveillance case definitions for human infection with novel coronavirus (nCoV). 2020; WHO/2019-nCoV/Surveillance/v2020.2.
- National Health Commission of the People's Republic of China. Prevention and treatment of pneumonia caused by new coronavirus infection. 2020. Available online: <http://www.nhc.gov.cn/>
- Garritty CM, Norris SL, Moher D. Developing WHO rapid advice guidelines in the setting of a public health emergency. *J Clin Epidemiol* 2017;82:47-60.
- World Health Organization. WHO handbook for guideline development: WHO, 2014.
- Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. *Clinical Practice Guidelines We Can Trust*. Washington (DC): National Academies Press (US); 2011.
- Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ* 2016; 352:i1152.
- Schünemann HJ, Wiercioch W, Etzeandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. *CMAJ* 2014;186:E123-42.
- Chen Y, Yang K, Marušić A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. *Ann Intern Med* 2017;166:128-32.
- Wang X, Chen Y, Yao L, et al. Reporting of declarations and conflicts of interest in WHO guidelines can be further improved. *J Clin Epidemiol* 2018;98:1-8.
- Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol* 2007;7:10.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
- Norris SL, Meerpohl JJ, Akl EA, et al. The skills and experience of GRADE methodologists can be assessed with a simple tool. *J Clin Epidemiol* 2016;79:150-8.e1.
- Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). *J Clin Epidemiol* 2011;64:407-15.
- Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *J Clin Epidemiol* 2011;64:1277-82.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. *J Clin Epidemiol* 2011;64:1283-93.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol* 2011;64:1294-302.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol* 2011;64:1303-10.
- Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol* 2011;64:1311-6.
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401-6.
- Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. *Lancet* 2017;390:415-23.

22. Raine R, Sanderson C, Black N. Developing clinical guidelines: A challenge to current methods. *BMJ* 2005;331:631-3.
23. Schünemann HJ, Hill SR, Kakad M, et al. Transparent development of the WHO rapid advice guidelines. *PLoS Med* 2007;4:e119.
24. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. Geneva: World Health Organization; 2006.
25. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization; 2011.
26. World Health Organization. Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization; 2010.
27. World Health Organization. Clinical management of adult patients with complications of pandemic influenza A (H1N1) 2009: emergency guidelines for the management of patients with severe respiratory distress and shock in district hospitals in limited-resource settings. Geneva: World Health Organization; 2010.
28. World Health Organization. Screening, assessment and management of neonates and infants with complications associated with Zika virus exposure in utero: rapid advice guideline. Geneva: World Health Organization; 2016.
29. Lamontagne F, Fowler RA, Adhikari NK, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. *Lancet* 2018;391:700-8.
30. Endocrinology Society of Chinese Medical Association, Chinese Pharmaceutical Association Hospital Pharmacy Committee. the Quick Advice Guideline for the Clinical Application of Incretin-Based Drug Therapy. *Chin J Endocrinol Metab* 2016;32:448-54.
31. Zhou P, Liang S, Zhai S. A Protocol Introduction of Rapid Advice Guideline for Intravenous Azithromycin in Pediatrics. *China Pharm* 2018;29:436-40.

Cite this article as: Li W, Zhou Q, Tang Y, Ren L, Yu X, Li Q, Liu E, Chen Y. Protocol for the development of a rapid advice guidelines for management of children with SARS-CoV-2 infection. *Ann Palliat Med* 2020. doi: 10.21037/apm.2020.02.33

Supplementary

	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	D12	D13	D14	D15	D16	D17	D18	D19	D20	D21	D22	D23	D24	D25	D26	D27	D28	D29	D30	D31
Launch the guideline																															
Write protocol																															
Invite panelists																															
Declare conflicts of interests																															
Register guideline																															
Proposal clinical questions																															
Priority clinical questions																															
PICO clinical questions																															
Retrieve existing systematic reviews																															
Conduct rapid reviews																															
GRADE evidence																															
Draft recommendations																															
Conduct the 1 st round of Delphi survey																															
Conduct the 2 nd round of Delphi survey																															
Reach recommendations																															
Draft full guideline																															
Send to external reviewers																															
Revise the guideline																															
Submit to medical journal																															
Translate the guideline																															

Note: D1=Jan 28, D31=Feb 29 (from Jan 28 to Feb 29).

Figure S1 Gantt Chart: key steps and timeline.

Box S1 Search strategy for PubMed

- #1. "Adolescent"[Mesh]
 - #2. "Infant"[Mesh]
 - #3. "Child"[Mesh]
 - #4. "Pediatrics"[Mesh]
 - #5. pediatric* [Title/Abstract]
 - #6. paediatric*[ti]
 - #7. child*[ti]
 - #8. infant*[ti]
 - #9. adolescent*[ti]
 - #10. Baby[ti]
 - #11. Babies[ti]
 - #12. trottie*[ti]
 - #13. youth*[ti]
 - #14. Kids[ti]
 - #15. toddler*[ti]
 - #16. pre-school*[ti]
 - #17. preschool*[ti]
 - #18. kindergarten*[ti]
 - #19. kinder-garten*[ti]
 - #20. girl*[ti]
 - #21. boy*[ti]
 - #22. student*[ti]
 - #23. junior*[ti]
 - #24. juvenile*[ti]
 - #25. neonat*[ti]
 - #26. newborn*[ti]
 - #27. teenager*[ti]
 - #28. Pubescent[ti]
 - #29. Preterm[ti]
 - #30. Puberty[ti]
 - #31. young*[ti]
 - #32. OR/#1-#31
 - #33. Coronavirus [Title/Abstract]
 - #34. "Middle East Respiratory Syndrome Coronavirus"[Title/Abstract]
 - #35. MERS[Title/Abstract]
 - #36. SARS[Title/Abstract]
 - #37. CoV[Title/Abstract]
 - #38. HCoV[Title/Abstract]
 - #39. 2019-CoV[Title/Abstract]
 - #40. "Wuhan-Cov"[Title/Abstract]
 - #41. "Wuhan Coronaviru*"
 - #42. "Coronavirus"[Mesh]
 - #43. "Middle East Respiratory Syndrome Coronavirus"[Mesh]
 - #44. "Coronavirus Infections"[Mesh]
 - #45. "SARS Virus"[Mesh]
 - #46. OR/#33-#45
 - #47. #32 AND #46
-

Table S1 GRADE Grid for voting recommendations

	GRADE score				
	1	2	0	-2	-1
Balance between desirable and undesirable consequences of intervention	Advantages obviously outweigh disadvantages	Advantage may outweigh disadvantage	Equal or uncertain	Disadvantages may outweigh advantages	Disadvantages obviously outweigh advantages
Recommendation	Strong recommendation	Weak recommendation	No specific recommendation	Weak recommendation	Strong recommendation
Voting results					